Menu Back to Canada-Annual-Meeting


Short Course: October 30 | Virtual

Short Course: November 2 | Virtual

Meeting: November 7-8 | In-Person

The DIA Canada Annual Meeting will deliver a comprehensive overview of the current pharmaceutical, medical device, and/or diagnostic landscapes in Canada, while sharing insights into Canada’s broader role in global healthcare product development and is separated into three tracks: Regulatory, Clinical and Pharmacovigilance. This meeting will connect attendees with leaders and experts in academia and those involved in the regulatory, clinical, and pharmacovigilance functional areas in the pharmaceutical and medical device industry to explore best practices, lessons learned, and problem-solving strategies effecting stakeholders in Canada.

Need approval in order to attend? Download and fill out our Justification Letter to demonstrate to your supervisor why this is a must-attend event.

Participant Testimonials

Very insightful conference. Time well invested.” - Thierry Page, Executive VP, COO, Starpax Biopharma Inc.

“The best conference for Canadian content of 2022.” - Patricia Smith, Director, Regulatory Affairs, QA and PV, Otsuka Canada Pharmaceutical Inc.


Want to learn more about Canada Annual Meeting? You've come to the right site!
DIA Global Annual Meeting


View our Exhibit Partners and explore our latest offerings

Learn more
Generic Highlights

Highlights & Features

Stay in the know with what's going on at the event

Learn more

Who should attend?

  • Meeting Designed For

    Join professionals interested in a comprehensive overview of the current biopharma pharmaceutical, medical device, and/or diagnostics landscape in Canada:

    • Pharmacovigilance and Drug Safety
    • Risk Management
    • Clinical Research, Management, and Operations
    • Regulatory Affairs and Operations
    • Medical Affairs and Scientific Communication
    • Quality Assurance
    • Life Sciences R&D
    • Project Management
    • Real-World Data and Real-World Evidence
    • Data Management

  • Learning Objectives

    At the conclusion of this activity, participants should be able to:

    • Contextualize the Agile Licensing for Drugs initiative within Health Canada’s (HC’s) Regulatory Innovation Agenda
    • Identify key themes and feedback heard during HC’s consultation period, including the use of terms and conditions, risk management plans, and rolling reviews
    • Describe current efforts to increase equitable drug development and regulatory systems
    • Identify regulatory frameworks and policies to support advanced therapeutic products and devices in Canada
    • Gain insights on international collaboration initiatives in place to support timely access to medicines in Canada
    • Define specific attributes of HC’s regulatory requirements on HC’s Nitrosamines Impurities Guidance and utilization of international collaboration to inform regulatory requirements and decisions
    • Gain insights on how to optimize clinical trials operationally in Canada
    • Identify the most common good pharmacovigilance practices (GVP) inspection findings
    • Gain insights on considerations around global collaboration and reliance regarding digital advancements in regulatory data transformation
    • Identify key elements of effective clinical supply chain
    • Define transparency requirements for sponsors and expectations from regulators
    • Register


Program Committee

  • Maria  Anillo
    Maria Anillo Regulatory Affairs Project Manager
    AstraZeneca Canada Inc., Canada
  • Marcia  Bailey, BSN, MHS, RN
    Marcia Bailey, BSN, MHS, RN Safety Evaluation and Risk Management Scientific Director
    GSK, Canada
  • Vatche  Bartekian, MSc
    Vatche Bartekian, MSc President
    Vantage BioTrials, Canada
  • Mandy  Collier
    Mandy Collier Director, Health Products and Food Branch
    Health Canada, Canada
  • Melanie  Cote, MS
    Melanie Cote, MS Senior Manager, Regulatory Affairs
    Otsuka , Canada
  • My  Dang
    My Dang Senior Manager, Regulatory Affairs and Quality Assurance
    Knight Therapeutics Inc. , Canada
  • Tharany  Ganesh, MSc
    Tharany Ganesh, MSc Director, Regulatory Affairs & Quality Assurance
    AstraZeneca Canada Inc., Canada
  • Lorella  Garofalo, PhD
    Lorella Garofalo, PhD Head of Regulatory Sciences
    Pfizer Canada, Canada
  • Marie-France  Goyer, MSc
    Marie-France Goyer, MSc Director, Clinical Operations
    Abcellera, Canada
  • Brenda  Gryfe, MSc
    Brenda Gryfe, MSc Director, Regulatory Affairs
    TPIreg/ Innomar Strategies, Canada
  • Oxana  Iliach, PhD
    Oxana Iliach, PhD Senior Director Regulatory Strategy
    Certara, Canada
  • Agnes  Jankowicz, MS
    Agnes Jankowicz, MS Vice President, Pharmacovigilance
    Veristat, Canada
  • Nadiya  Jirova, MSc
    Nadiya Jirova, MSc Manager, Bureau of Biologics, Radiopharmaceuticals and Self-Care Products
    Health Canada, Canada
  • Yatika  Kohli, PhD, MBA
    Yatika Kohli, PhD, MBA Chief Regulatory and Strategy Officer
    NoNO Inc, Canada
  • Nadia  Mian, MS
    Nadia Mian, MS Pharmacovigilance Manager
    Ipsen Biopharmaceuticals Canada Inc, Canada
  • Myriam  Salem, MSc
    Myriam Salem, MSc Senior Corporate Regulatory and Enforcement Advisor
    Health Canada, Canada
  • Marcia  Sam
    Marcia Sam Regulatory Affairs Strategy and Policy Manager
    Hoffmann-La Roche Canada Limited, Canada
  • Vanessa  Zapata
    Vanessa Zapata Associate Director, Regional Pharmacovigilance Officer
    Merck Canada Inc., Canada
  • Zohra  Douida, MPharm, MS, MSc
    Zohra Douida, MPharm, MS, MSc Head, Regulatory Affairs Canada
    Indivior Canada Inc., Canada
  • Amber  McLeod, PhD
    Amber McLeod, PhD Lead, Regulatory Affairs
    Abbvie Corporation, Canada
  • Representative Invited
    Representative Invited DIA, United States
Load More